ArchiveMarch 2011

Disease activity-free status: the new gold standard?

Could we use disease-activity free status to determine the effectiveness of new MS disease-modifying therapies? It may make it easier to do head-to-head studies.
Please see the following links:
Coles et al. Lancet Neurol. 2011 Apr;10(4):338-48.

Giovannoni et al. Lancet Neurol. 2011 Apr;10(4):329-337.

EMA approves Fingolimod for RRMS

European Commission approves Fingolimod, the first oral multiple sclerosis treatment for use in the EU. (1) Fingolimod is approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS. (2) Fingolimod showed superior efficacy to interferon beta-1a IM, a commonly prescribed...



Recent Posts

Recent Comments